Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : US1101221083
Compare
Compare
Traded in other countries / regions
BMY.USA0R1F.UKBRM.GermanyBMY.MexicoBMY.PeruBMY.Argentina1BMY.ItalyBMYS.AustriaBMYB34.BrazilBMY.Switzerland IPO Date
2023-11-13Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 3 | |||||
| Debt-to-EBITDA | 10.14 | |||||
| Interest Coverage | 4.12 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.58 | |||||
| Beneish M-Score | -3.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.8 | |||||
| 3-Year EBITDA Growth Rate | 62.2 | |||||
| 3-Year EPS without NRI Growth Rate | 5.3 | |||||
| 3-Year FCF Growth Rate | 1.1 | |||||
| 3-Year Book Growth Rate | -5.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.01 | |||||
| 9-Day RSI | 68.45 | |||||
| 14-Day RSI | 67.97 | |||||
| 6-1 Month Momentum % | 30.53 | |||||
| 12-1 Month Momentum % | 7.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.24 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.36 | |||||
| Days Inventory | 88.89 | |||||
| Days Sales Outstanding | 69.53 | |||||
| Days Payable | 103.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.97 | |||||
| Dividend Payout Ratio | 2.08 | |||||
| 3-Year Dividend Growth Rate | 7.9 | |||||
| Forward Dividend Yield % | 3.94 | |||||
| 5-Year Yield-on-Cost % | 5.83 | |||||
| 3-Year Average Share Buyback Ratio | 3.1 | |||||
| Shareholder Yield % | -5.45 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.91 | |||||
| Operating Margin % | 15.35 | |||||
| Net Margin % | -15.3 | |||||
| FCF Margin % | 28.99 | |||||
| ROE % | -33.27 | |||||
| ROA % | -7.66 | |||||
| ROIC % | 9.22 | |||||
| ROC (Joel Greenblatt) % | -63.15 | |||||
| ROCE % | -7.17 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.28 | |||||
| PE Ratio without NRI | 50.62 | |||||
| Shiller PE Ratio | 44.02 | |||||
| PEG Ratio | 2.07 | |||||
| PS Ratio | 2.53 | |||||
| PB Ratio | 7.01 | |||||
| Price-to-Free-Cash-Flow | 8.71 | |||||
| Price-to-Operating-Cash-Flow | 8.01 | |||||
| EV-to-EBIT | -31.96 | |||||
| EV-to-Forward-EBIT | 9.34 | |||||
| EV-to-EBITDA | 32.23 | |||||
| EV-to-Forward-EBITDA | 8.82 | |||||
| EV-to-Revenue | 3.45 | |||||
| EV-to-Forward-Revenue | 3.49 | |||||
| EV-to-FCF | 11.84 | |||||
| Price-to-Projected-FCF | 0.84 | |||||
| Price-to-DCF (Earnings Based) | 1.85 | |||||
| Price-to-DCF (FCF Based) | 0.29 | |||||
| Price-to-Median-PS-Value | 0.69 | |||||
| Earnings Yield (Greenblatt) % | -3.13 | |||||
| FCF Yield % | 11.49 | |||||
| Forward Rate of Return (Yacktman) % | 14.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bristol-Myers Squibb Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 43,489.63 | ||
| EPS (TTM) (€) | -3.309 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 67.97 | ||
| 14-Day ATR (€) | 0.760071 | ||
| 20-Day SMA (€) | 53.948 | ||
| 12-1 Month Momentum % | 7.85 | ||
| 52-Week Range (€) | 36 - 56.7 | ||
| Shares Outstanding (Mil) | 2,028.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bristol-Myers Squibb Co Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bristol-Myers Squibb Co Frequently Asked Questions
What is Bristol-Myers Squibb Co(MIL:1BMY)'s stock price today?
The current price of MIL:1BMY is €55.97. The 52 week high of MIL:1BMY is €56.70 and 52 week low is €36.00.
When is next earnings date of Bristol-Myers Squibb Co(MIL:1BMY)?
The next earnings date of Bristol-Myers Squibb Co(MIL:1BMY) is 2025-02-06.
Does Bristol-Myers Squibb Co(MIL:1BMY) pay dividends? If so, how much?
The Dividend Yield %  of Bristol-Myers Squibb Co(MIL:1BMY) is 3.97% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(MIL:1BMY) was 2.08. The lowest was 0.27. And the median was 0.38. The  Forward Dividend Yield % of Bristol-Myers Squibb Co(MIL:1BMY) is 3.94%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers